OraSure Technologies Inc (OSUR)

Price$4.04

Value ScoreA

Growth ScoreD

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)61.82%

Price vs S&P 500 (4W)32.04%

VGM Score65.42

Market Capitalization$278.15M

All Metrics

P/CF (Annual)7.82x

Book Value / Share (Quarterly)$4.51

P/TBV (Annual)0.54x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-33.29%

Cash Flow / Share (Quarterly)$-0.69

Price vs S&P 500 (YTD)58.78%

Gross Margin (TTM)42.54%

Net Profit Margin (TTM)-66.42%

EPS (TTM)$-1.04

10-Day Avg Trading Volume0.96M

EPS Excl Extra (TTM)$-1.04

Revenue Growth (5Y)-7.70%

EPS (Annual)$-0.94

ROI (Annual)-20.16%

Gross Margin (Annual)42.22%

Net Profit Margin (5Y Avg)-14.30%

Cash / Share (Quarterly)$2.55

Revenue Growth QoQ (YoY)-6.70%

ROA (Last FY)-17.05%

Revenue Growth TTM (YoY)-30.08%

EBITD / Share (TTM)$-1.00

ROE (5Y Avg)-4.68%

Operating Margin (TTM)-68.56%

Cash Flow / Share (Annual)$-0.76

P/B Ratio0.89x

P/B Ratio (Quarterly)0.66x

Net Income / Employee (Annual)$-137,500

EV / Revenue (TTM)0.90x

Net Interest Coverage (TTM)-70.76x

ROA (TTM)-18.19%

EV / EBITDA (TTM)5.88x

EPS Incl Extra (Annual)$-0.94

Current Ratio (Annual)6.58x

Quick Ratio (Quarterly)4.66x

3-Month Avg Trading Volume0.57M

52-Week Price Return43.77%

EV / Free Cash Flow (Annual)-0.10x

Revenue / Employee (TTM)$226,000

Tangible BV / Share (Quarterly)$4.24

P/S Ratio (Annual)2.42x

Asset Turnover (Annual)0.29x

52-Week High$4.33

Operating Margin (5Y Avg)-16.00%

EPS Excl Extra (Annual)$-0.94

CapEx CAGR (5Y)-32.03%

Tangible BV CAGR (5Y)-3.31%

26-Week Price Return69.75%

Quick Ratio (Annual)5.67x

13-Week Price Return35.12%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.46x

Enterprise Value$101.41M

Revenue / Share Growth (5Y)-9.26%

Asset Turnover (TTM)0.27x

Book Value / Share Growth (5Y)-2.73%

Revenue / Employee (Annual)$230,000

Inventory Turnover (Annual)2.04x

Pretax Margin (Annual)-56.15%

Cash / Share (Annual)$2.83

3-Month Return Std Dev50.74%

Gross Margin (5Y Avg)43.21%

Net Income / Employee (TTM)$-150,100

ROE (Last FY)-20.17%

Net Interest Coverage (Annual)-33.20x

EPS Basic Excl Extra (Annual)$-0.94

P/FCF (TTM)4.35x

Receivables Turnover (TTM)4.88x

EV / Free Cash Flow (TTM)4.96x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.04

Receivables Turnover (Annual)5.00x

ROI (TTM)-21.48%

P/S Ratio (TTM)2.46x

Pretax Margin (5Y Avg)-11.83%

Revenue / Share (Annual)$1.57

Tangible BV / Share (Annual)$4.57

Free OCF CAGR (5Y)117.00%

Price vs S&P 500 (52W)19.41%

Year-to-Date Return66.94%

5-Day Price Return-1.22%

EPS Normalized (Annual)$-0.94

ROA (5Y Avg)-3.81%

Net Profit Margin (Annual)-59.76%

Month-to-Date Return-6.05%

Cash Flow / Share (TTM)$0.96

EBITD / Share (Annual)$-0.90

Operating Margin (Annual)-62.57%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-4.67%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.04

P/TBV (Quarterly)0.70x

P/B Ratio (Annual)0.51x

Inventory Turnover (TTM)1.97x

Pretax Margin (TTM)-62.24%

Book Value / Share (Annual)$4.84

Price vs S&P 500 (13W)26.86%

Beta1.03x

P/FCF (Annual)11.80x

Revenue / Share (TTM)$1.62

ROE (TTM)-21.50%

52-Week Low$2.08

vGradeA

gGradeD

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.32est. -0.19

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.00

4.13

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
OSUROraSure Technologies Inc	A	D	B	$4.04
SYKStryker Corporation	C	C	C	$305.66
MMM3M Company	C	F	C	$153.76
BSXBoston Scientific Corp.	C	B	D	$48.55
MDLNMedline Inc. Class A common stock	C	D	D	$33.61
BDXBecton, Dickinson and Co.	B	C	C	$151.16
RMDResMed Inc.	C	B	C	$196.04
DXCMDexCom, Inc.	C	B	C	$72.86
WSTWest Pharmaceutical Services, Inc.	D	C	B	$314.50
SOLVSolventum Corporation	C	D	B	$81.01
PENPenumbra, Inc.	F	C	B	$320.53

About

OraSure Technologies manufactures oral fluid diagnostic devices and specimen collection kits for infectious disease testing. The diagnostics segment provides rapid tests for HIV and HCV, while the larger molecular solutions segment offers collection and transport kits for genetic material and infectious disease screening, including COVID-19 testing. The company generates the majority of its revenue from molecular solutions, primarily serving U.S. customers.